You must be registered and logged in to participate, click here to login. If you do not already have an account, click here to register.
This course is for nurses and provides ANCC credit as described below. If you are seeking AANP credit for participation, click here.
|Release Date: 7/15/2019||Expiration Date: 7/14/2020||Estimated Time to Complete: 1.5 hours|
This program was recorded at the ONS 44th Annual Congress in Anaheim, California on April 10, 2019. Topics include the latest developments in diagnosing and treating myeloid malignancies; emerging treatment options for low-risk MDS, high-risk MDS, AML, and MDS/MPN overlap; disease management for chronic anemia, side effects and treatment adherence; psychosocial considerations and palliative care to improve the quality of life for this patient population. Case studies are used to illustrate treatment decision-making and therapeutic challenges.
- Explain the role of genetic testing in diagnosing, stratifying and treating myeloid malignancies;
- Identify emerging treatment options for patients with low-risk MDS, high-risk MDS, secondary AML, and MDS/MPN overlap;
- Analyze the nurse’s role in managing treatment for myeloid malignancies based on clinical presentations, diagnostic workups, transfusion dependence, and comorbidities;
- Discuss the nurse’s role in collaboration with other disciplines in addressing treatment goals and providing patient education to improve outcomes.
Nancy Corbitt, BSN, RN, OCN, CRNI, University of Maryland Greenebaum Cancer Center, Baltimore, MD
- Tiffany Tanaka, MD, Division of Regenerative Medicine, UC San Diego Moores Cancer Center, San Diego, CA
- Costandina Herbert, BSN, RN, Seattle Cancer Care Alliance, Seattle, WA
- Chris Onderdonk, LCSW, Doris A. Howell Palliative Care Service, UC San Diego Hillcrest Hospital, San Diego, CA
This activity is jointly provided by Medical Learning Institute, Inc. and the Aplastic Anemia and MDS International Foundation.
Commercial Support Acknowledgement
This activity is supported by an educational grant from Celgene Corporation
This activity was developed for nurses and nurse practitioners who are involved in the treatment or management of patients with bone marrow failure disease
Nursing Education Purpose Statement
The purpose of this activity is to improve the knowledge and competence of nurses concerning the treatment or management of patients with bone marrow failure disease
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours
Method of Participation
There are no fees for participating in and receiving credit for this activity. Participants must:
- read the learning outcomes and faculty disclosures
- watch and study the educational activity
- complete the appropriate post-test (one is for nurse credits and one for nurse practitioner credits), a passing score of 70% or better is required for nurses and nurse practitioners
- complete the evaluation form
- Once you’ve completed the appropriate steps and scored a 70% or above, your certificate will be emailed to you from our accrediting company MLI. Please allow a few business days for the certificate to arrive.